(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2011 (07.04.2011)

PCT

(10) International Publication Number
WO 2011/039096 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) *A61P 3/08* (2006.01)
C07K 14/575 (2006.01) *A61P 5/48* (2006.01)
C07K 14/605 (2006.01) *A61K 47/48* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2010/064020

(22) International Filing Date:
23 September 2010 (23.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/247,346 30 September 2009 (30.09.2009) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HAMILTON, Bruce** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **HERRING, Christopher** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **PAULIK, Mark, Andrew** [US/US]; GlaxoSmithKline, Five Moore Drive, P O Box 13398, Durham, North Carolina 27703 (US).

(74) Agents: **WILSON (married name: KUCERNAK), Lynn** et al.; GlaxoSmithKline, Global Patents CS925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: DRUG FUSIONS AND CONJUGATES WITH EXTENDED HALF LIFE




Figure 4

(57) Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.

WO 2011/039096 A1

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*